initial public offerings (IPOs) trading on American exchanges

Monday, February 3, 2014

Dicerna Pharmaceuticals Inc (DRNA) began trading on the NASDAQ on 30 January 2014

  • Priced 6 million shares of common stock at $15.00 per share.
  • Jefferies LLC, Leerink Partners LLC, and Stifel, Nicolaus & Company, Incorporated are acting as joint book-running managers for the offering. Robert W. Baird & Co. Incorporated is acting as co-lead manager for the offering.


Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. The Company intends to discover, develop and commercialize therapeutics either on its own or in collaboration with pharmaceutical partners. The Company has partnered two of its oncology development programs with the global pharmaceutical company Kyowa Hakko Kirin Co., Ltd. The Company is developing DCR-PH1 for the treatment of the rare and serious inherited disorder PH1 by targeting the liver metabolic enzyme glycolate oxidase.


Building 1 Suite 120, 480 Arsenal Street
United States 

Key stats and ratios

Q3 (Sep '13)2012
Net profit margin--144.28%
Operating margin--131.86%
EBITD margin--124.01%
Return on average assets-56.86%-58.12%
Return on average equity--

No comments:

Post a Comment